NCIRS वेबिनार: आगामी राष्ट्रीय टीकाकरण कार्यक्रम में बदलाव: आपको क्या जानना चाहिए
1 जुलाई 2020 को राष्ट्रीय टीकाकरण कार्यक्रम (एनआईपी) में महत्वपूर्ण बदलाव और न्यूमोकोकल, मेनिंगोकोकल और हेपेटाइटिस ए के टीकाकरण की सिफारिशें प्रभावी होंगी।
NCIRS 16 जून को दोपहर 1 बजे (AEST) इन परिवर्तनों के बारे में एक वेबिनार की मेजबानी कर रहा है। नीचे दिए गए लिंक पर वेबिनार के लिए पंजीकरण करें:
NCIRS: आगामी NIP परिवर्तन: आपको क्या जानने की आवश्यकता है
अंडा-एलर्जी वाले बच्चों में पीले बुखार का टीकाकरण
येलो फीवर मच्छर वेक्टर द्वारा प्रेषित एक बीमारी है, जिससे गंभीर जटिलताएं या मृत्यु भी हो सकती है। उपचार सहायक है, रोग को रोकने में टीकाकरण सबसे महत्वपूर्ण रणनीति है; टीका प्राप्त करने वाले 95% से अधिक लोगों में प्रतिरक्षा प्रदान करना। वर्तमान में, कई दिशानिर्देश सलाह देते हैं कि एग एनाफिलेक्सिस एक पीले बुखार के टीके (YFV) प्राप्त करने के लिए एक contraindication है, ऑस्ट्रेलियन इम्युनाइजेशन हैंडबुक के साथ जिन लोगों को वैक्सीन की आवश्यकता होती है, वे YFV युक्त एग ओवलब्यूमिन के कारण इम्यूनोलॉजिस्ट या एलर्जिस्ट के साथ इस पर चर्चा करते हैं।
रोग की गंभीर प्रकृति के कारण, कुछ देशों में प्रवेश की आवश्यकता के रूप में टीकाकरण के प्रमाण की आवश्यकता होती है और अंडा-एलर्जी वाले लोगों में वाईएफवी से संबंधित व्यापक रूप से भिन्न दिशानिर्देश; नेशनल सेंटर फॉर इम्यूनाइजेशन रिसर्च एंड सर्विलांस (NCIRS) और मेलबर्न में रॉयल चिल्ड्रन हॉस्पिटल के शोधकर्ताओं ने एक केस सीरीज़ प्रकाशित की है जिसमें प्रस्ताव दिया गया है कि हल्के अंडे की एलर्जी वाले रोगियों के लिए त्वचा परीक्षण की आवश्यकता नहीं हो सकती है, और यह कि 2-स्टेप ग्रेडेड चुनौती चिकित्सकीय देखरेख में एक सुरक्षित विकल्प है।
यहां उनके निष्कर्षों और सिफारिशों के बारे में और पढ़ें:
बाल चिकित्सा संक्रामक रोग जर्नल: ईजीजी एलर्जी वाले बच्चों में पीला बुखार टीकाकरण
NCIRS: एग-एलर्जिक बच्चों में येलो फीवर टीकाकरण
1 जुलाई, 2020 से NIP में आगामी परिवर्तन
1 जुलाई, 2020 को राष्ट्रीय टीकाकरण कार्यक्रम (एनआईपी) में कई बदलाव होंगे:
नि:शुल्क एनआईपी न्यूमोकोकल टीकों के लिए पात्रता (प्रीवेनर 13®, न्यूमोवैक्स 23®)
- 65 वर्ष की आयु में स्वस्थ गैर-स्वदेशी वयस्कों के लिए न्यूमोवैक्स 23® बंद करना
- ≥70 वर्ष की आयु के स्वस्थ गैर-स्वदेशी वयस्कों के लिए प्रीवेनर 13® शुरू करना
- स्वदेशी वयस्कों के लिए प्रीवेनर 13® की शुरुआत ≥50 वर्ष की आयु के साथ साथ जीवन भर न्यूमोवैक्स 23® x 2 खुराक
- 12 महीने से अधिक उम्र (किशोरों और वयस्कों सहित) के लिए Prevenar 13® शुरू करना, नए जोखिम की स्थिति के साथ साथ Pneumovax 23® x 2 जीवन भर की खुराक
- जोखिम स्थितियों के लिए नए पात्रता मानदंड
नि:शुल्क एनआईपी मेनिंगोकोकल बी (बेक्ससेरो®) टीके के लिए पात्रता:
- आदिवासी और टोरेस स्ट्रेट आइलैंडर शिशुओं को Bexsero® की 2 प्राथमिक खुराक और 1 बूस्टर खुराक मिलती है - 2, 4 और 12 महीने की उम्र में
- Bexsero® कैच-अप सभी आदिवासी और टोरेस स्ट्रेट आइलैंडर बच्चों <2 साल की उम्र के लिए 3 साल तक 30 जून 2023 तक उपलब्ध है
- जोखिम की स्थिति वाले कुछ लोग Bexsero® के पात्र होंगे
परिवर्तनों के बारे में यहाँ और पढ़ें:
COVID19 Road to a vaccine episode 2: Professor Kathryn Edwards
- Professor Edwards' perspective on vaccine safety across her roles as a clinician/scientist/researcher
- Adverse events following immunisation and their implications when developing new vaccines
- Vaccine safety across the different phases (I to IV) of clinical trials
- The importance of data safety and monitoring committees in vaccine trials
- What we can learn from the historical research into the development of SARS and MERS vaccines
- What is ADE (antibody-dependent enhancement of virus infection) and why is it an important consideration in COVID19 vaccine development?
- What are adjuvants and how does the use of them affect safety planning?
- Should pregnant women and children be involved in vaccine trials and how can their participation be managed safely?
- The importance of transparency and honest communication with the public in regards to vaccine safety
You can listen to the episode via our podcast page or via the links below:
COVID19 Road to a vaccine episode 1: Professor Stanley Plotkin
In Episode 1 of our new podcast series, Associate Professor Nigel Crawford, a vaccinologist and consultant paediatrician at the Murdoch Children’s Research Institute (MCRI) & Royal Children’s Hospital (RCH), Melbourne, talks with Stanley Plotkin, Emeritus Professor of Paediatrics at the University of Pennsylvania; who is well known internationally for his role in vaccine development.
In this episode they discuss:
- Professor Plotkin’s role in the development of the rubella vaccine, still used throughout the world today
- His role as the Editor in Chief of the ‘Vaccines’ textbook
- His role in the formation of the Coalition for Epidemic Preparedness and Innovation (CEPI) and CEPI’s current role in global COVID-19 vaccine development
- What can we learn from the H1N1 pandemic in the development of a COVID-19 vaccine?
- How developing a vaccine against coronaviruses is critical to the future of civilisation as economies are being destroyed by these viruses
- Human challenge models and some of the ethical considerations we need to tackle if these sorts of trials are going to be undertaken to support COVID-19 vaccine development
- Success can only be achieved through global collaboration in the pursuit of a COVID-19 vaccine
- How the practical aspects of distributing a vaccine on this scale have never been faced before and the importance of thinking outside the box!
संसाधन:
- Plotkin's Vaccines (7th edition)
- Vaccine: Extraordinary diseases require extraordinary solutions
- CEPI: Coalition for Epidemic Preparedness and Innovation
Listen to the episode here:
स्प्रेकर - Apple Podcasts - Spotify Podcasts
Special MVEC podcast series: COVID19 Road to a vaccine
The year 2020 has seen the emergence of the SARS-CoV-2 virus (COVID19), a unique and potentially devastating virus, with no known prevention or treatment. This new SARS-2 virus has shown to not only have significant international health implications, but also immense psychological and economic impacts. Associate Professor Nigel Crawford, a vaccinologist and consultant paediatrician at the Murdoch Children’s Research Institute (MCRI) & Royal Children’s Hospital (RCH), Melbourne, will delve into the global pursuit of a safe and effective vaccine to prevent COVID19. This is all occurring at ‘pandemic speed’ and MVEC’s new podcast will explore this complicated and multi-faceted process through interviews with a variety of national and international vaccine experts.
In our first few episodes, we will be talking with vaccine experts Emeritus Professor Stanley Plotkin, Professor Kathryn Edwards and Professor Andrew Pollard.
Listen via our podcast page or subscribe below on your preferred podcast platform:
स्प्रेकर - Apple podcasts - Spotify podcasts
Who's leading the race? A guide to coronavirus vaccines in the pipeline
This article from the ABC takes a closer look at some of the candidates in the race to making an effective SARS-CoV-2 vaccine. It looks at the ten vaccines currently in human trials (as at May 24, 2020).
Different kinds of vaccines in development are also discussed, both an experimental genetic vaccine as well as a viral vector vaccine; and which stage of trials these vaccines are currently at.
Read more here:
ABC: Who's leading the race? A guide to coronavirus vaccines in the pipeline
Stay tuned for our latest podcast series launching this week, COVID19 Road to a vaccine. Associate Professor Nigel Crawford, Director of SAEFVIC, will be discussing the different steps involved in creating a new vaccine with global vaccine experts.
Hepatitis A outbreak in Victoria
There is an ongoing hepatitis A outbreak in Victoria largely among people use drugs (primarily by injection) and people experiencing homelessness. According to the Department of Health, as of the 6th May 2020, there have been 56 confirmed cases and 6 possible cases associated with this outbreak since mid 2019.
In order to control this outbreak a hepatitis A vaccination program targeting affected people groups (people who use drugs and those experiencing homelessness) will be available until the 31st August, 2020.
Hepatitis B vaccine should also be offered as hepatitis B and C have a high rate of prevalence among people who inject drugs. Influenza vaccine should also be offered.
Read the full Department of Health advisory here: Hepatitis A outbreak
New NCIRS resource - Influenza vaccination during COVID-19 - FAQs for Aboriginal and Torres Strait Islander people
Aboriginal and Torres Strait Islander people are at an increased risk of serious disease when they contract influenza. During the current COVID-19 pandemic, it is more important than ever that Aboriginal Torres Strait Islander people are accessing an influenza vaccine. The influenza vaccine is funded under the National Immunisation Program for all Aboriginal and Torres Strait Islander people aged 6-months and over.
NCIRS have created a new FAQ resource addressing questions most frequently asked by people in the Aboriginal and Torres Strait Islander community:
NCIRS: Influenza vaccination during COVID-19 - FAQs for Aboriginal and Torres Strait Islander people
Are children with asthma at a greater risk of severe disease with COVID-19?
The Murdoch Children’s Research Institute (MCRI) are conducting extensive research into why children are more mildly affected by COVID-19. They are also investigating whether chronic health conditions such as asthma increase the risk of severe disease.
Read more about how children with asthma may be affected by COVID-19 at the link below:
MCRI: COVID-19 and asthma: what are the risks for children?